Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Gentian Diagnostics makes and sells laboratory tests that help hospitals and clinics detect and monitor diseases, especially kidney problems and infections.
Gentian Diagnostics is a small Norwegian company that makes the chemical tests that hospitals and labs run on blood samples. When a doctor wants to know how well your kidneys are working, or whether you have a serious infection, a lab machine somewhere has to measure tiny molecules in your blood. Gentian makes the ingredients and test kits that let that machine give a reliable answer.
The company's best-known product is a kidney test called cystatin C. Doctors have long used a different marker, creatinine, to check kidney function, but it can mislead: it depends on how much muscle you have, so a muscular person and a frail elderly person can look very different even with the same kidneys. Cystatin C is less sensitive to muscle mass, so it can catch kidney problems that the old test misses. Gentian is one of the few companies that makes this test in a form that runs on the big automated lab machines hospitals already own, which means labs can add it without buying new equipment. Its other main line is a marker called calprotectin, used to tell whether an infection is bacterial and to track inflammation in the gut. Hospitals, clinical labs, and the companies that distribute lab products are the customers. They pay Gentian for test kits and the raw materials that go into them, usually through partners who sell and distribute the products in each country. The pitch is straightforward: better answers on machines labs already have. The risk is equally straightforward. This is a niche business up against giant diagnostic companies with far bigger salesforces, and it depends on winning regulatory approvals and convincing lab managers to switch from tests they already trust.
Gentian is headquartered in Nærsnes, Norway, not far from Oslo, and it sells into markets across Europe and beyond. It is a small company, with annual revenue in the low hundreds of millions of Norwegian kroner, and it has spent years pushing cystatin C toward wider use rather than sitting on one product. That bet — that labs will gradually move to a better kidney marker — is the whole story of the business in miniature.
Saved answer · last researched 15 Nov 2026